Literature DB >> 17102110

Risk-oriented approach to hereditary adrenal pheochromocytoma.

Andreas Machens1, Michael Brauckhoff, Oliver Gimm, Henning Dralle.   

Abstract

Hereditary adrenal pheochromocytoma is caused by germline mutations in RET, VHL, SDHB, SDHD, and NF1. As these genes differ in function, so may their pheochromocytoma phenotypes, suggesting gene-specific patterns of age-related progression to pheochromocytoma. This possibility was explored for gene carriers with a lifetime risk of pheochromocytoma in excess of 50%. Published age-standardized penetrance rates of VHL-, SDHB-, and SDHD-associated pheochromocytoma were gauged against age-standardized penetrance rates of MEN2-associated pheochromocytoma in 219 institutional carriers of RET mutations conferring highest (codon 918), high (codons 609, 611, 618, 620, 630, and 634) and least high risk (codons 768, 790, 791, 804, and 891). The highest-risk category included SDHB, SDHD, and the highest-risk RET genotype; the high-risk category VHL missense mutations and the high-risk RET genotypes; and the least-high risk category VHL truncating mutations and least-high risk RET genotypes. Detailed information on recurrence rates and intervals was available only for the RET carriers (19-31% and means of 4.3-5.5 years; all RET risk categories combined). Ipsilateral recurrences in adrenal remnants, and contralateral recurrences in virgin adrenals were comparable in incidence (27% and 39%, P=0.69; high-risk RET category) and time to recurrence (means of 4.3 vs. 5.4 year; P>0.99; high-risk RET category), discounting a major effect of tumor spillage at primary subtotal adrenalectomy on pheochromocytoma recurrence. The risk of malignancy usually is low, except for SDHB (38%). For most hereditary pheochromocytomas, endoscopic subtotal adrenalectomy is the procedure of choice. Grouping hereditary pheochromocytoma into preliminary risk categories may improve the management of gene carriers at risk of developing pheochromocytomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17102110     DOI: 10.1196/annals.1353.045

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

1.  Bilateral adrenal pheochromocytoma with a germline L790F mutation in the RET oncogene.

Authors:  Jun Won Min; Youn Joon Park; Hee Jin Kim; Myung-Chul Chang
Journal:  J Korean Surg Soc       Date:  2012-02-27

2.  Minimally Invasive Surgery (MIS) in Children and Adolescents with Pheochromocytomas and Retroperitoneal Paragangliomas: Experiences in 42 Patients.

Authors:  Martin K Walz; Laura D Iova; Judith Deimel; Hartmut P H Neumann; Birke Bausch; Stefan Zschiedrich; Harald Groeben; Pier F Alesina
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

Review 3.  [Adrenalectomy for preservation of adrenocortical function. Indication and results].

Authors:  M K Walz
Journal:  Chirurg       Date:  2009-02       Impact factor: 0.955

Review 4.  A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.

Authors:  Ioannis Ilias; Karel Pacak
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

5.  RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest.

Authors:  Eliska Vaclavikova; Sarka Dvorakova; Vlasta Sykorova; Radovan Bilek; Katerina Dvorakova; Petr Vlcek; Richard Skaba; Tomas Zelinka; Bela Bendlova
Journal:  Endocrine       Date:  2009-10-14       Impact factor: 3.633

6.  The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.

Authors:  Sonali Thosani; Montserrat Ayala-Ramirez; Lynn Palmer; Mimi I Hu; Thereasa Rich; Robert F Gagel; Gilbert Cote; Steven G Waguespack; Mouhammed Amir Habra; Camilo Jimenez
Journal:  J Clin Endocrinol Metab       Date:  2013-09-12       Impact factor: 5.958

Review 7.  [Function-preserving adrenalectomy for adrenal tumors].

Authors:  M Brauckhoff; H Dralle
Journal:  Chirurg       Date:  2012-06       Impact factor: 0.955

Review 8.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

Review 9.  A Guide to Pheochromocytomas and Paragangliomas.

Authors:  Julie Guilmette; Peter M Sadow
Journal:  Surg Pathol Clin       Date:  2019-09-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.